Non‐Surgical Periodontal Therapy and Metformin Improve Bone Loss in Obese Mice With Periodontitis by Modulating the Gut Microbiota
Open Access
- 9 July 2025
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 39 (13) , e70814
Abstract
Periodontitis and obesity are chronic inflammatory diseases associated with osteoporosis. Controlling inflammation is crucial for managing periodontitis in individuals with obesity. Metformin has shown potent anti‐inflammatory effects under inflammatory conditions. However, the effects of adjunctive systemic administration of metformin alongside non‐surgical periodontal therapy (NSPT) on periodontal and systemic bone health in obesity remain unknown. In this study, a high‐fat diet (HFD)‐induced obese murine model was created with periodontitis through ligation. Periodontal treatment consisted of standard mechanical debridement via NSPT, with or without metformin treatment through oral gavage. Outcomes were evaluated based on changes in periodontal status, systemic bone resorption and inflammation, as well as the gut microbiota community and metabolism. Our results indicated that periodontitis significantly increased osteoclastic activity and resulted in alveolar and femoral bone loss in HFD‐fed mice. Compared to NSPT alone, NSPT and metformin significantly improved periodontitis, reduced systemic inflammation, and alleviated femoral bone absorption in HFD‐fed mice. Mechanistically, periodontitis promoted gut microbiota dysbiosis and disrupted microbial linoleic acid metabolism. NSPT and metformin normalized the gut microbiota, enhanced the growth of species with anti‐inflammatory properties, including Faecalibacterium prausnitzii , Akkermansia muciniphila , Lactobacillus reuteri , and Butyricicoccus pullicaecorum , and restored the balance of linoleic acid metabolism in the gut and serum. This research presents novel evidence that metformin may serve as a promising adjunct to enhance the response of obese subjects to NSPT by regulating the gut microbiota and linoleic acid metabolism, indicating that the gut microbiota could be a potential therapeutic target for multidisciplinary intervention in periodontitis and obesity.Keywords
Funding Information
- National Natural Science Foundation of China (82270979)
This publication has 58 references indexed in Scilit:
- Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri‐Implant Diseases and ConditionsJournal of Clinical Periodontology, 2018
- Metformin Alters Upper Small Intestinal Microbiota that Impact a Glucose-SGLT1-Sensing Glucoregulatory PathwayCell Metabolism, 2018
- Levels of serum retinol‐binding protein 4 before and after non‐surgical periodontal treatment in lean and obese subjects: An interventional studyJournal of Clinical Periodontology, 2017
- Bacterial conjugated linoleic acid production and their applicationsProgress in Lipid Research, 2017
- Effects of metformin on inflammation, oxidative stress, and bone loss in a rat model of periodontitisPLOS ONE, 2017
- Diet–microbiota interactions as moderators of human metabolismNature, 2016
- TNF biology, pathogenic mechanisms and emerging therapeutic strategiesNature Reviews Rheumatology, 2015
- Metformin: From Mechanisms of Action to TherapiesCell Metabolism, 2014
- A core gut microbiome in obese and lean twinsNature, 2008
- Impaired skeletal development in interleukin‐6–transgenic mice: A model for the impact of chronic inflammation on the growing skeletal systemArthritis & Rheumatism, 2006